Hill expands ephedra investigation
This article was originally published in The Tan Sheet
Former Yellow Jackets manufacturer NVE Pharmaceuticals is latest firm to receive House Energy & Commerce Committee letter as part of its ongoing ephedra investigation. Correspondence, sent April 21, asks NVE President Robert Occhifinto to disclose information on its marketing practices and AEs related to sale of Yellow Jackets. Committee also recently expanded its inquiry to include PediaLean children's weight-loss supplement (1"The Tan Sheet" April 14, 2003, p. 4). Yellow Jackets and NVE were the subject of an FDA investigation and concurrent Senate subcommittee hearing in October 2002 (2"The Tan Sheet" Oct. 14, 2002, p. 6). Firm has until May 5 to respond...
You may also be interested in...
"Pro-steroid" and "precursor steroid" products' proliferation in the dietary supplement market "raise[s] questions about whether additional federal action should be taken," according to the House Energy & Commerce Committee
FDA is in the process of inspecting NVE Pharmaceuticals' Newton, N.J. plant, where Yellow Jacket ephedra/caffeine supplements are manufactured
Singulair’s Psychiatric AE Risks Still A Problem, But US FDA Has Limited Mitigation Options Remaining
Stakeholders suggested a ‘Dear Healthcare Provider’ letter or speaking about the risks to professional societies to emphasize the psychiatric adverse events that prompted a boxed warning for the now-generic asthma drug montelukast. The NY Attorney General is adding more pressure.